In Case You Missed: Utilizing the Muscarinic System to Optimize Treatment Options for Schizophrenia
This activity is supported by an educational grant from Karuna Therapeutics.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Karuna Therapeutics.
Activity Description
Schizophrenia is an incurable, neuropsychiatric disease characterized by difficulties thinking and communicating clearly as well as psychosis (ie, “positive” symptoms); difficulty functioning socially (ie, “negative” symptoms); and cognitive impairment. As many as 34% of patients with schizophrenia have treatment-resistant schizophrenia, defined as continuing symptoms despite at least 2 trials of appropriate antipsychotic treatment, and most people do not recover from it. Patients with schizophrenia have a shortened lifespan, with as many as 10% committing suicide. Most current treatments for schizophrenia have focused on dopamine (ie, first-generation antipsychotics, second-generation antipsychotics), which can improve the positive symptoms of schizophrenia. However, these therapies are associated with side effects including extrapyramidal symptoms (EPS) as well as metabolic side effects, in addition to increased risk of cardiometabolic problems, hyperprolactinemia, sexual dysfunction, and menstrual irregularities. Currently, there is no available therapy to improve the negative symptoms of schizophrenia. In recent years, elucidation of the role of muscarinic acetylcholine receptors in the pathogenesis of schizophrenia has increased. The development and investigation of agents targeting the muscarinic system has shown that these agents may be new treatment options for patients with schizophrenia and have shown to improve the negative symptoms of schizophrenia. In this educational activity, expert faculty will review the role of the muscarinic system in the pathogenesis of schizophrenia and will evaluate the latest clinical trial data on emerging muscarinic receptor-targeting agents for the treatment of schizophrenia.
Target Audience
The intended audience for this activity is psychiatrists, physician associates, nurse practitioners, and other healthcare professionals involved in the management of patients with schizophrenia.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Understand the role of the muscarinic system in schizophrenia.
- Evaluate the latest data on emerging muscarinic agents for the treatment of schizophrenia.
Activity Chair
Diana O. Perkins, MD, MPH
Professor, Department of Psychiatry
University of North Carolina at Chapel Hill
Chapel Hill, NC
Faculty
Anissa Abi-Dargham, MD
Chair, Department of Psychiatry and Behavioral Health
Distinguished Professor
Stony Brook University
Stony Brook, NY
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY, USA
Professor and Chair, Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Linda A. Giarraputo, BS, PA-C
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, June 16, 2023, to June 15, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate or AAPA Category 1 CME certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Anissa Abi-Dargham, MD
No relevant financial relationships to disclose.
Christoph U. Correll, MD
Advisor: AbbVie, Allergan, Angelini, Biogen, Gedeon Richter, Janssen/J&J Vision, Karuna, Lundbeck
Consultant: AbbVie, Acadia, Alkermes, Allergan, Angelini, Cerevel, Gedeon Richter, Holmusk, Intra-Cellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedinCell, Merck, MindPax, Mylan, Neurocrine Biosciences, Noven, Otsuka, Pfizer, Pharmabrain, PPD, Recordati, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon Pharma, Sunovion, Supernus, Takeda, Teva, Viatris
Speaker Contracted by Ineligible Company: AbbVie, Angelini, Aristopharma, Darnitsa, Gedeon Richter, Hikema Pharmaceuticals, Intra-Cellular Therapies, Janssen/J&J, Lundbeck, Mitsubishi Tananbe, Mylan, Otsuka, Recordati, Seqirus, Sunovion, Takeda, Viatris
Independent Research Contractor: Janssen, Takeda
Individual Stocks and Stock Options: LB Pharma, PsiloSterius, The Quantic Group
Diana O. Perkins, MD, MPH
Consultant: Alkermes
Planners/Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Linda A. Giarraputo, BS, PA-C
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com